About Us

We are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The history of our Group can be traced back to June 2007, when Dr. Liang, our Chairman and Chief Scientific Officer, established Sichuan Clover to develop a new generation of biologics based on the Trimer-Tag™ technology platform he invented.

Timeline

2007
June 2007,Sichuan Clover was established as a research laboratory

2011
December 2011,We completed the Angel Round Investment and raised RMB10 million

2015
November 2015,Sichuan Clover completed an IND filing for SCB-808

December 2015,Sichuan Clover initiated GLP studies on SCB-313 at the National Shanghai Center for New Drug Safety Evaluation and Research

2016
January 2016,Sichuan Clover commenced research on its HIV subunit vaccine

July 2016,Sichuan Clover entered into an agreement to establish and build 32,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, Zhejiang Province, China

2017
December 2017,We completed the Series A Investment and raised approximately RMB62.8 million

2018
June 2018,The first patient in a Phase 1 clinical trial was dosed with SCB-313 for treatment of malignant ascites in cancer patients

2019
November 2019,We completed the Series B Investment and raised approximately RMB304.1 million

2020
January 2020,We initiated development of SCB-2019, our COVID-19 vaccine candidate

April 2020,We obtained funding from and established collaboration with CEPI for SCB-2019 (CpG 1018/Alum)

June 2020,We completed the Series B-2 Investment and raised approximately RMB171.8 million

June 2020,The first participant in a Phase 1 clinical trial was dosed with SCB-2019 (CpG 1018/Alum)

November 2020,CEPI extended our partnership and increased funding up to $328 million for SCB-2019 development through licensure

December 2020,We announced positive Phase 1 data for SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidate

2021
February 2021,We completed the Series C financing raising approximately US$230 million

March 2021,We initiated SPECTRA, a pivotal global Phase 2/3 clinical trial evaluating SCB 2019 (CpG 1018/Alum) for vaccine efficacy and dosed the first participant at a clinical trial site located in the Philippines

June 2021,Global enrollment of SPECTRA surpassed 29,000 adult and elderly participants resulting in one of the most ethnically diverse COVID-19 clinical trials conducted to date

June 2021,We completed an advanced purchase agreement with GAVI to supply up to 414 million doses of our COVID-19 vaccine candidate for procurement through the COVAX Facility

June 2021,We completed a commercial supply agreement with Dynavax for their CpG 1018 adjuvant for use in our COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum)

July 2021,CEPI additionally endorsed US$32.8 million to a total of up to US$360.5 million for SCB-2019 (CpG 1018/Alum) CMC activities.

September 2021,We announced SCB-2019 (CpG 1018/Alum) met the primary and secondary efficacy endpoints in SPECTRA , our global pivotal Phase 2/3 clinical trial

November 2021,We were listed on the Hong Kong Stock Exchange

November 2021,Our COVID-19 Vaccine Candidate has been administered as heterologous booster in investigator-led phase 2 clinical trial

December 2021,We signed COVID-19 vaccine supply agreement with UNICEF

2022
January 2022,We dosed first participants with homologous booster dose of COVID-19 vaccine candidate in SPECTRA

March 2022,We announced positive clinical results of SCB-2019 (CpG 1018/Alum) demonstrates durable high protection and immune responses against omicron as a booster

May 2022,Our Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern

May 2022,We dosed first participants in Phase 1 Trial with SCB-2020S, a potentially broadly protective chimeric COVID-19 vaccine candidate

June 2022,We dosed first participants in Phase 3 Trial evaluating SCB-2019 as a heterologous COVID-19 booster following prior vaccination with inactivated, mRNA or viral vector vaccines

June 2022,We dosed first patient with SCB-219M in Phase 1 Trial for chemotherapy-ionduced thrombocytopenia